logo

Medicinova Inc (MNOV)



Trade MNOV now with
  Date
  Headline
1/31/2018 7:11:32 AM MediciNova Announces Presentation Of SPRINT-MS Phase 2b Study Of MN-166 In Progressive MS At The ACTRIMS Forum
11/10/2017 1:37:25 AM MediciNova Appoints Hideki Nagao To Its Board
10/26/2017 6:11:29 AM MediciNova Unveils Positive Top-Line Results From SPRINT-MS Phase 2b Trial Of MN-166 In Progressive MS
9/19/2017 6:02:16 AM MediciNova Completes Enrollment In Phase 2 Clinical Trial Of MN-166 (ibudilast) In Methamphetamine Dependence
8/30/2017 6:05:35 AM MediciNova Announces Abstract From MN-166 SPRINT-MS Phase 2b Study In Progressive MS Accepted For Platform Presentation
4/9/2017 7:57:21 PM MediciNova Announces MN-166 Glioblastoma Abstract Selected For Presentation
2/6/2017 6:04:09 PM MediciNova Presents Positive Findings From Completed Trial Of MN-166 (ibudilast) In Methamphetamine Dependence
12/9/2016 6:04:04 AM MediciNova Presents Exploratory Interim Clinical Outcomes Data From Clinical Trial Of MN-166 In ALS
10/30/2016 8:41:02 PM MediciNova Announces MN-166 ALS Abstract Accepted For Presentation
10/11/2016 8:52:58 PM MediciNova Announces FDA Granted Orphan Drug Designation To MN-166 For Amyotrophic Lateral Sclerosis
7/13/2016 6:31:48 AM MediciNova Begins Interim Efficacy Analysis In Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS